Back to Authors

Lee, Jung‐Min

https://orcid.org/0000-0001-5456-7449

Mayo Clinic

National Cancer Institute

Citations 1

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
Barry, William T., Wenham, Robert M. , Hendrickson, Andrea E. Wahner , Armstrong, Deborah K. , Chan, Nancy , Lee, Jung‐Min , Penson, Richard T. , Cristea, Mihaela , Abbruzzese, James L. , Matsuo, Koji , Olawaiye, Alexander , Farooq, Sarah , Kohn, Elise C. , Matulonis, Ursula A. , Liu, Joyce F. , Cohn, David E. , Swisher, Elizabeth M. , Van Allen, Eliezer M , Shapiro, Geoffrey I. , Ivy, S. Percy

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5519-5519

10.1200/jco.2018.36.15_suppl.5519 Get It